Detalles de la búsqueda
1.
Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial.
Eur Heart J
; 45(13): 1159-1169, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38291599
2.
Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial.
Eur Heart J
; 42(47): 4821-4829, 2021 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34537830
3.
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.
Circulation
; 141(8): 616-623, 2020 02 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-31707849
4.
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
Circulation
; 141(20): 1600-1607, 2020 05 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32223429
5.
Long-Term Incidence of Stroke and Dementia in ASCOT.
Stroke
; 52(10): 3088-3096, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34192893
6.
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjectsã- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial.
Circ J
; 85(11): 2063-2070, 2021 10 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33980763
7.
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
Circulation
; 139(12): 1483-1492, 2019 03 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-30586750
8.
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
Stroke
; 51(5): 1546-1554, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32312223
9.
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
N Engl J Med
; 376(18): 1713-1722, 2017 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28304224
10.
Cognitive Function in a Randomized Trial of Evolocumab.
N Engl J Med
; 377(7): 633-643, 2017 08 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-28813214
11.
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Circulation
; 137(4): 338-350, 2018 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29133605
12.
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
Circulation
; 138(8): 756-766, 2018 08 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-29626068
13.
Inflammatory and Cholesterol Risk in the FOURIER Trial.
Circulation
; 138(2): 131-140, 2018 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29530884
14.
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Lancet
; 390(10106): 1962-1971, 2017 Oct 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28859947
15.
Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL.
Circulation
; 144(21): 1732-1734, 2021 11 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34452583
16.
Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy.
Circulation
; 144(3): 249-251, 2021 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34279993
17.
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.
Am Heart J
; 173: 94-101, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26920601
18.
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.
Eur Heart J
; 36(24): 1536-46, 2015 Jun 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25802390
19.
Clinical benefits of evolocumab appear less than hoped - Authors' reply.
Lancet
; 391(10124): 934-935, 2018 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29536853
20.
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.
Eur Heart J
; 33(4): 486-94, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21798891